|
Minghao Sun
Vice President of Research and Product Development
capricor therapeutics
san diego, California
USA
|
Dr. Sun joined Capricor in 2021 and is currently serving as our Vice President of Research and Product Development where he oversees Capricor’s exosome platform and pipeline development as well as process development for CAP-1002. He has approximately 15 years of experience in biotechnology combining his extensive molecular and virology knowledge with multiple years of expertise in exosome research. As an innovator in the exosome field, Dr. Sun has focused on the design of exosome engineering constructs, loading, targeting and manufacturing for multiple exosome-based product candidates.
Prior to joining Capricor, Dr. Sun served as the Head of In Vitro Pharmacology (IVP) at Wuxi AppTec, a global pharmaceutical company, where he oversaw the IVP activities, strategy as well as initiated new business opportunities to drive the revenue growth. Prior to joining Wuxi AppTec, Dr. Sun was Director of Stem Cell Research at TransOva Genetics, a global leader in reproductive technology. Prior to that, he worked at Intrexon Corp., where he held positions of increasing responsibility, including, antibody discovery, stem cell research, and managing multiple exosome-related programs leading to multiple product candidates where he was head and general manager of their San Diego site.
Dr. Sun received his B.A. in Virology and M.S. in Medical Virology from Wuhan University, China. He then earned his Ph.D. in Pathobiology from Penn State University and completed his postdoctoral training in oncology in Dr. Peter Vogt’s lab at Scripps Research Institute in San Diego, California.
Prior to joining Capricor, Dr. Sun served as the Head of In Vitro Pharmacology (IVP) at Wuxi AppTec, a global pharmaceutical company, where he oversaw the IVP activities, strategy as well as initiated new business opportunities to drive the revenue growth. Prior to joining Wuxi AppTec, Dr. Sun was Director of Stem Cell Research at TransOva Genetics, a global leader in reproductive technology. Prior to that, he worked at Intrexon Corp., where he held positions of increasing responsibility, including, antibody discovery, stem cell research, and managing multiple exosome-related programs leading to multiple product candidates where he was head and general manager of their San Diego site.
Dr. Sun received his B.A. in Virology and M.S. in Medical Virology from Wuhan University, China. He then earned his Ph.D. in Pathobiology from Penn State University and completed his postdoctoral training in oncology in Dr. Peter Vogt’s lab at Scripps Research Institute in San Diego, California.